Customer Services:

Global: Service@Genexo-Tech.com

China: Service-cn@Genexo-Tech.com

Call Center (US):

+1-800-968-3721(Toll Free)

Fax (US):

+1-800-931-7968

US Office:

4400 Route 9 South, Suite 3100, Freehold, NJ 07728

China Office:

Room 1016, Reignwood Centre, No.8
Jianguomenwai Ave, Beijing 100022

Message Feedback

  • Dr. Yu Zhou, MD, PhD

    Founder and Co-Chief Executive Officer

    Dr. Yu Zhou MD, PhD, founder and Co-Chief Executive Officer of the Company. Dr. Zhou carries out groundbreaking research in the clinical application of gene therapy, stem cell therapy and non-cell-based exosome therapy for diseases including neurodegeneration diseases, fibrotic diseases, and cancers. His research has been continuously funded, and he has authored over 30 peer reviewed scientific publications.

    Dr. Zhou discovered and pioneered the field of exosome biology and focuses on the discovery of biomarkers carried by circulating exosomes and other microvesicles. He also demonstrated that stem cell derived exosomes cargo growth factors and “regeneration” messengers to stimulate cell growth. As a principal inventor of two U.S. patents, Dr. Zhou continues to pioneer critical advancements in the field of exosome biology.

    From 2007-2017, Dr. Zhou has served as senior scientist in the Department of Pediatric Surgery at Nationwide Children’s Hospital. He pursued postdoctoral training in pathology and molecular biology at the University of Montreal, Canada and the National Institute of Health (NIH), USA. He graduated from XiangYa School of medicine and completed his residency training in general surgery and fellowship training in plastic surgery, both at XiangYa Second Hospital of Central South University, China.

  • Dr. David Jin, MD, PhD

    Co-Chief Executive Officer

    Dr. David Jin, MD, PhD, a director and Chief Executive Officer of the Company.

    From 2009 to 2016, Dr. Jin has served as the Chief Medical Officer of BioTime, Inc. (NYSE MKT: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology.

    Dr. Jin also acts as a senior translational clinician-scientist at the Howard Hughes Medical Institute and the Ansary Stem Cell Center at Weill Cornell Medical College of Cornell University.

    Prior to his current endeavors, Dr. Jin was Chief Consultant/Advisor for various biotech/pharmaceutical companies regarding hematology, oncology, immunotherapy and stem cell-based technology development. Dr. Jin has been Principle Investigator in more than 15 pre-clinical and clinical trials, as well as author/co-author of over 80 peer-reviewed scientific abstracts, articles, reviews, and book chapters.

    Dr. Jin studied medicine at SUNY Downstate College of Medicine in Brooklyn, NY. He received his clinical training and subsequent faculty tenure at the New York-Presbyterian Hospital (the teaching hospital for both Cornell and Columbia Universities) in the areas of internal medicine, hematology, and clinical oncology. Dr. Jin was honored as Top Chief Medical Officer by ExecRank in 2012, as well as recognized as Leading Physicians of the World in 2015.

  • Meng Li

    Chief Operating Officer

    Ms. Li is Chief Operating Officer of the Company.

    Ms. Li has over 15 years of executive experience in international marketing, branding, communication, and media investment consultancy.

    Ms. Li served as Managing Director at Maxus/GroupM (a WPP Group company) where she was responsible for business P&L and corporate management from 2006 to 2015. Prior to joining Maxus/Group M, Ms. Li worked for Zenithmedia (a Publicis Group company) from 2000-2006 as Senior Manager.

    Ms. Li received a Bachelor of Arts in International Economic Law from University of Dalian Maritime University, China.